AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2017

Nov 3, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AGIOS PHARMACEUTICALS INC (AGIO)
CIK: 0001439222
Period of Report: 2017-11-01

Reporting Person: Biller Scott (Chief Scientific Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-11-01	Common stock	M	2146	$31.64	Acquired	8410	Direct
2017-11-01	Common stock	S	100	$65.45	Disposed	8310	Direct
2017-11-01	Common stock	S	200	$63.62	Disposed	8110	Direct
2017-11-01	Common stock	S	900	$63.09	Disposed	7210	Direct
2017-11-01	Common stock	S	946	$61.81	Disposed	6264	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-11-01	Stock option (right to buy)	$31.64	M	2146	Disposed	2024-03-04	Common stock (2146)	Direct

Footnotes

F1: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $63.60 to $63.63. The
reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer,
to provide full information regarding the number of shares sold at each separate price.

F4: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $62.57 to $63.49. The
reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer,
to provide full information regarding the number of shares sold at each separate price.

F5: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $61.36 to $62.34. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F6: This option was granted on March 5, 2014. The shares underlying this option vest as to 25% of the shares on March 5, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter.